Brendan de Kauwe
Follow
Get notifications in MyBN when activity occurs.
Upgrade your subscription to use this feature.
Brendan de Kauwe
Managing Director / Attollo Capital
Most Notable Role
Dr Brendan de Kauwe is Director of Attollo Capital, with a decade of experience in venture capital, M&A, Public Offerings (IPOs, ICOs), reverse mergers, international equity capital markets and debt instruments. Brendan is an internationally experienced operations and transaction focused executive and has served as Chairman and/or Director of numerous publicly (NASDAQ, ASX) listed technology (blockchain, FinTech) and biotech companies and private enterprises. He is the CoFounder and CEO of SOLIS, a multinational entertainment blockchain and production company.
Dr de Kauwe studied a Bachelor of Science in Physiology and Pharmacology and holds a Bachelor of Dental Surgery from the University of Western Australia, with additional Post Graduate certifications in Oral Surgery and Implantology. He also holds a Post Graduate Diploma in Applied Finance, majoring in Corporate Finance, is the Responsible Manager for a Retail and Wholesale Australian Financial Services Licence (AFSL) and is an ASIC complaint (RG146) Securities Advisor. He holds a Diploma of Music Industry (Sound Engineering) and Multimedia.
Dr de Kauwe studied a Bachelor of Science in Physiology and Pharmacology and holds a Bachelor of Dental Surgery from the University of Western Australia, with additional Post Graduate certifications in Oral Surgery and Implantology. He also holds a Post Graduate Diploma in Applied Finance, majoring in Corporate Finance, is the Responsible Manager for a Retail and Wholesale Australian Financial Services Licence (AFSL) and is an ASIC complaint (RG146) Securities Advisor. He holds a Diploma of Music Industry (Sound Engineering) and Multimedia.
Lists and Charts
Roles
Year started and most recent title
Share Transactions
Total value as at the date of the transaction
Powered by Morningstar ®
Person Activity
| NEW ROLE: Managing Director, Attollo Capital | 12 May 2022 |
| REMUNERATION UPDATE: Non-Executive Director, Ookami | 24 Aug 2020 |
| REMUNERATION UPDATE: Non-Executive Director, Ookami | 30 Jun 2020 |
News Articles
Related Information
Positions - Current
| Position | Company | Year | Company's current rank | WA staff |
|---|---|---|---|---|
| Non-Executive Director | | 2017 | ||
| Managing Director | | 2015 |
Positions - Previous
| Position | Company | Year | Company's current rank |
|---|---|---|---|
| Non-Executive Director | | 2015 - 2020 | |
| Director (since 2015) | | 2012 - 2020 | |
| Non-Executive Director | | 2016 - 2018 | |
| Non-Executive Director (Chair 2016-Feb 2018) | | 2016 - 2018 | |
| Non-Executive Director | | 2017 - 2017 | |
| Director | | 2015 - 2016 | |
| Executive Director (Executive Chair 2014-2015) | | 2013 - 2015 | |
| Non-Executive Director | | 2013 - 2014 |
Directors Interests
| Company | Date | Transaction type | Number of shares | Price per share | Transaction value | Nature of change |
|---|---|---|---|---|---|---|
| Ookami | 16 Feb 2018 | Other | 9,000,000 | OtherConversion of securities | ||
| Ookami | 16 Feb 2018 | Issued | 9,000,000 | OtherConversion of securities | ||
| G Medical Innovations Holdings | 05 Sep 2017 | Bought | 795,455 | OtherConversion of securities | ||
| G Medical Innovations Holdings | 05 Sep 2017 | Other | 795,455 | OtherConversion of securities: 1363636- Performance Rights | ||
| Actinogen Medical | 01 Dec 2014 | Bought | 2,500,000 | $0.02 | $50,000 | Placement |
Powered by Morningstar ®
Equity Capital Markets Deals
| Date | Company | Transaction Type | Total Value | |
|---|---|---|---|---|
| 08/09/14 | Actinogen Medical | Placement | $2.0m | >> |
Mergers & Acquisitions Deals
| Announced | Bidder | Target | Transaction Type | Total Value | |
|---|---|---|---|---|---|
| 27/08/14 | Actinogen Medical | Corticrine | Acquisition | $5.8m | >> |
| 22/03/17 | Pharmanet Group | Keras Resources, Calidus Resources | Reverse takeover | $4.5m | >> |
